A Soluble Epoxide Hydrolase Inhibitor, 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) Urea, Ameliorates Experimental Autoimmune Encephalomyelitis

Polyunsaturated fatty acids (PUFAs) are essential FAs for human health. Cytochrome P450 oxygenates PUFAs to produce anti-inflammatory and pain-resolving epoxy fatty acids (EpFAs) and other oxylipins whose epoxide ring is opened by the soluble epoxide hydrolase (sEH/Ephx2), resulting in the formation of toxic and pro-inflammatory vicinal diols (dihydroxy-FAs). Pharmacological inhibition of sEH is a promising strategy for the treatment of pain, inflammation, cardiovascular diseases, and other conditions. We tested the efficacy of a potent, selective sEH inhibitor, 1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea (TPPU), in an animal model of multiple sclerosis (MS), experimental autoimmune encephalomyelitis (EAE). Prophylactic TPPU treatment significantly ameliorated EAE without affecting circulating white blood cell counts. TPPU accumulated in the spinal cords (SCs), which was correlated with plasma TPPU concentration. Targeted lipidomics in EAE SCs and plasma identified that TPPU blocked production of dihydroxy-FAs efficiently and increased some EpFA species including 12(13)-epoxy-octadecenoic acid (12(13)-EpOME) and 17(18)-epoxy-eicosatrienoic acid (17(18)-EpETE). TPPU did not alter levels of cyclooxygenase (COX-1/2) metabolites, while it increased 12-hydroxyeicosatetraenoic acid (12-HETE) and other 12/15-lipoxygenase metabolites. These analytical results are consistent with sEH inhibitors that reduce neuroinflammation and accelerate anti-inflammatory responses, providing the possibility that sEH inhibitors could be used as a disease modifying therapy, as well as for MS-associated pain relief.

[1]  Jun Yang,et al.  Plasma Linoleate Diols Are Potential Biomarkers for Severe COVID-19 Infections , 2021, Frontiers in Physiology.

[2]  Nicholas E. Propson,et al.  An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer’s disease , 2020, Science Translational Medicine.

[3]  F. Piehl Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis , 2020, Journal of internal medicine.

[4]  I. Božić,et al.  Astrocyte phenotypes: Emphasis on potential markers in neuroinflammation. , 2020, Histology and histopathology.

[5]  J. Gommerman,et al.  Regulation of neuroinflammation by B cells and plasma cells , 2020, Immunological reviews.

[6]  A. Gomes,et al.  Soluble Epoxide Hydrolase Regulation of Lipid Mediators Limits Pain , 2020, Neurotherapeutics.

[7]  Meryem Temiz-Reşitoğlu,et al.  Pharmacological inhibition of soluble epoxide hydrolase attenuates chronic experimental autoimmune encephalomyelitis by modulating inflammatory and anti-inflammatory pathways in an inflammasome-dependent and -independent manner , 2020, Inflammopharmacology.

[8]  T. Nagatake,et al.  17(S),18(R)‐epoxyeicosatetraenoic acid generated by cytochrome P450 BM‐3 from Bacillus megaterium inhibits the development of contact hypersensitivity via G‐protein‐coupled receptor 40‐mediated neutrophil suppression , 2019, FASEB bioAdvances.

[9]  Y. Tseng,et al.  Lipokines and Thermogenesis. , 2019, Endocrinology.

[10]  V. Yong,et al.  When encephalitogenic T cells collaborate with microglia in multiple sclerosis , 2019, Nature Reviews Neurology.

[11]  L. Wilkins Erratum: Lymphopenia and DMTs for relapsing forms of MS: Considerations for the treating neurologist. , 2019, Neurology. Clinical practice.

[12]  S. Hwang,et al.  In vitro and in vivo Metabolism of a Potent Inhibitor of Soluble Epoxide Hydrolase, 1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea , 2019, Front. Pharmacol..

[13]  S. Subramaniam,et al.  LIPID MAPS: Serving the next generation of lipid researchers with tools, resources, data, and training , 2019, Science Signaling.

[14]  J. Chun,et al.  Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders. , 2019, Annual review of pharmacology and toxicology.

[15]  M. Mayford,et al.  A Functionally Defined In Vivo Astrocyte Population Identified by c-Fos Activation in a Mouse Model of Multiple Sclerosis Modulated by S1P Signaling: Immediate-Early Astrocytes (ieAstrocytes) , 2018, eNeuro.

[16]  M. Ishii,et al.  The 17,18‐epoxyeicosatetraenoic acid–G protein–coupled receptor 40 axis ameliorates contact hypersensitivity by inhibiting neutrophil mobility in mice and cynomolgus macaques , 2017, The Journal of allergy and clinical immunology.

[17]  F. Haj,et al.  Modulation of mitochondrial dysfunction and endoplasmic reticulum stress are key mechanisms for the wide-ranging actions of epoxy fatty acids and soluble epoxide hydrolase inhibitors. , 2017, Prostaglandins & other lipid mediators.

[18]  Hong-feng Jiang,et al.  Hydroxyeicosapentaenoic acids and epoxyeicosatetraenoic acids attenuate early occurrence of nonalcoholic fatty liver disease , 2017, British journal of pharmacology.

[19]  S. Subramaniam,et al.  Computational Modeling of Competitive Metabolism between ω3- and ω6-Polyunsaturated Fatty Acids in Inflammatory Macrophages. , 2016, The journal of physical chemistry. B.

[20]  Moses Rodriguez,et al.  Untargeted Plasma Metabolomics Identifies Endogenous Metabolite with Drug-like Properties in Chronic Animal Model of Multiple Sclerosis* , 2015, The Journal of Biological Chemistry.

[21]  J. Chun,et al.  Dimethyl fumarate inhibits integrin α4 expression in multiple sclerosis models , 2015, Annals of clinical and translational neurology.

[22]  T. Maniatis,et al.  An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral Cortex , 2014, The Journal of Neuroscience.

[23]  Shankar Subramaniam,et al.  Modeling of eicosanoid fluxes reveals functional coupling between cyclooxygenases and terminal synthases. , 2014, Biophysical journal.

[24]  B. Hammock,et al.  Soluble epoxide hydrolase: gene structure, expression and deletion. , 2013, Gene.

[25]  R. Albadine,et al.  17,18-epoxyeicosatetraenoic acid targets PPARγ and p38 mitogen-activated protein kinase to mediate its anti-inflammatory effects in the lung: role of soluble epoxide hydrolase. , 2010, American journal of respiratory cell and molecular biology.

[26]  Paul D. Jones,et al.  1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain. , 2010, Journal of medicinal chemistry.

[27]  N. Tubridy,et al.  T cells in multiple sclerosis and experimental autoimmune encephalomyelitis , 2010, Clinical and experimental immunology.

[28]  S. Narumiya,et al.  Dual roles of PGE2-EP4 signaling in mouse experimental autoimmune encephalomyelitis , 2010, Proceedings of the National Academy of Sciences.

[29]  M. Fukayama,et al.  The leukotriene B4 receptor, BLT1, is required for the induction of experimental autoimmune encephalomyelitis. , 2010, Biochemical and biophysical research communications.

[30]  S. Akira,et al.  Targeted lipidomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis , 2009, Proceedings of the National Academy of Sciences.

[31]  Jun Yang,et al.  Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry. , 2009, Analytical chemistry.

[32]  Takao Shimizu,et al.  Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. , 2009, Annual review of pharmacology and toxicology.

[33]  Takao Shimizu,et al.  Platelet-Activating Factor Production in the Spinal Cord of Experimental Allergic Encephalomyelitis Mice via the Group IVA Cytosolic Phospholipase A2-Lyso-PAFAT Axis1 , 2008, The Journal of Immunology.

[34]  S. Shaikh,et al.  Polyunsaturated fatty acids and membrane organization: elucidating mechanisms to balance immunotherapy and susceptibility to infection. , 2008, Chemistry and physics of lipids.

[35]  P. Calabresi,et al.  Agar-gelatin for embedding tissues prior to paraffin processing. , 2007, BioTechniques.

[36]  S. Kusunoki,et al.  Selective COX-2 inhibitor celecoxib prevents experimental autoimmune encephalomyelitis through COX-2-independent pathway. , 2006, Brain : a journal of neurology.

[37]  Lawrence Steinman,et al.  How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis , 2006, Annals of neurology.

[38]  Takao Shimizu,et al.  Dual phase regulation of experimental allergic encephalomyelitis by platelet-activating factor , 2005, The Journal of experimental medicine.

[39]  J. Leonard,et al.  Cytosolic phospholipase A2α–deficient mice are resistant to experimental autoimmune encephalomyelitis , 2005, The Journal of experimental medicine.

[40]  S. LeVine,et al.  Experimental allergic encephalomyelitis is exacerbated in mice deficient for 12/15-lipoxygenase or 5-lipoxygenase , 2004, Brain Research.

[41]  R. Proia,et al.  Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 , 2004, Nature.

[42]  B. Hammock,et al.  The simultaneous quantification of cytochrome P450 dependent linoleate and arachidonate metabolites in urine by HPLC-MS/MS DOI 10.1194/jlr.D200018-JLR200 , 2002, Journal of Lipid Research.

[43]  H. Rosen,et al.  Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists , 2002, Science.

[44]  B. Hammock,et al.  Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase , 1997, Nature Medicine.

[45]  J. O'brien,et al.  Lipid composition of the normal human brain: gray matter, white matter, and myelin. , 1965, Journal of lipid research.

[46]  Y. Kihara,et al.  Druggable Lipid GPCRs: Past, Present, and Prospects. , 2020, Advances in experimental medicine and biology.

[47]  B. Hammock,et al.  Epoxy Fatty Acids Are Promising Targets for Treatment of Pain, Cardiovascular Disease and Other Indications Characterized by Mitochondrial Dysfunction, Endoplasmic Stress and Inflammation. , 2020, Advances in experimental medicine and biology.

[48]  C. H. Serezani,et al.  Targeting Leukotrienes as a Therapeutic Strategy to Prevent Comorbidities Associated with Metabolic Stress. , 2020, Advances in experimental medicine and biology.

[49]  E. Ricciotti,et al.  Druggable Prostanoid Pathway. , 2020, Advances in experimental medicine and biology.

[50]  Y. Kihara Systematic Understanding of Bioactive Lipids in Neuro-Immune Interactions: Lessons from an Animal Model of Multiple Sclerosis. , 2019, Advances in experimental medicine and biology.

[51]  M. Filippi,et al.  Multiple sclerosis. , 2018, Nature reviews. Disease primers.

[52]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.